Arovella Therapeutics Ltd has released a press release.
ALA-101 confers survival benefit in leukemia model
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
In the deck
Earlier from Arovella Therapeutics
- Arovella completes $1.65M placement
- R&D Tax Incentive refund received
- Europe Patent granted for iNKT Cell Therapy Platform
- Arovella to close its Perth OroMist R&D Facility
- Preclinical trial of ALA iNKT therapy and IMU onCARlytics
Later from Arovella Therapeutics
- Response to ASX Aware Query
- Response to ASX Query
- Arovellas OroMist R&D facility closure completed
- Arovella completes $4M placement & launches $1M spp
- Share Purchase Plan (SPP) Offer Booklet
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics